about
Imaging of multiple myeloma: Current conceptsRecognizing and treating secondary osteoporosisOsteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.Current developments in salivary diagnostics.Low bone-mineral density in patients with HIV: pathogenesis and clinical significance.SDF-1 inhibition targets the bone marrow niche for cancer therapy.Osteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection.The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression.Myeloma as a model for the process of metastasis: implications for therapyRole of the microenvironment in multiple myeloma bone disease.Treatment of spinal epidural compression due to hematological malignancies: a single institution's retrospective experienceVertebral Augmentation Involving Vertebroplasty or Kyphoplasty for Cancer-Related Vertebral Compression Fractures: A Systematic ReviewCombination with third-generation bisphosphonate (YM529) and interferon-alpha can inhibit the progression of established bone renal cell carcinoma.PTHrP produced by myeloma plasma cells regulates their survival and pro-osteoclast activity for bone disease progression.Bisphosphonates and statins inhibit expression and secretion of MIP-1α via suppression of Ras/MEK/ERK/AML-1A and Ras/PI3K/Akt/AML-1A pathways.Bone marrow microenvironment and tumor progression.Diffuse large B-cell lymphoma presenting with hypercalcemia and multiple osteolysis.Osteoclast-like cell formation by circulating myeloma B lymphocytes: role of RANK-L.Panoramic and skull imaging may aid in the identification of multiple myeloma lesions.Automated Whole-Body Bone Lesion Detection for Multiple Myeloma on 68Ga-Pentixafor PET/CT Imaging Using Deep Learning Methods.Percutaneous vertebroplasty in multiple myeloma: prospective long-term follow-up in 106 consecutive patients.Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential.RANKL inhibition: Clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases
P2860
Q26864616-CB5886B4-7E12-44D8-A842-562F20E86356Q28270738-05A96F85-3B0A-4D92-88B9-7AD594ADF3D6Q33564854-2E521EDD-B19E-486F-934A-7864D9AEA226Q33803001-4B8DD634-5327-4E39-9B58-E9C053718FBDQ33844059-F3B5C2EC-EDE6-4A8A-9B55-31F7C7CA4010Q34324830-6FD0CB03-2552-4D41-A5FC-AA1F68C5D5C8Q35572441-320288D3-8122-4361-ACDD-1460220D32A4Q35883830-1CBDC623-36B0-4C47-B5EF-EA0FBC017E33Q36079800-651DEE7A-548D-46E3-9497-98ABE6B438C8Q36512521-2CC48FA6-5C5A-45E0-9CBE-F06363333BF8Q36648562-9E44E232-F72A-4C5A-83DC-076F63561938Q36994303-B8D1744A-6B87-446F-9023-AA9D7F7B3B25Q38867820-054CE3AA-A1FD-4A48-8E93-BD5C06A12334Q39137073-B3E26E09-63D4-46CC-AE29-B682FB6D2CA7Q42027903-C5FB9456-6547-43DA-A258-7E4F3654BB1BQ43164811-AEEF04D3-4778-4155-94EA-936D243479BCQ47722823-AC852695-E454-49EB-8328-AF8D098D850EQ47722850-F091D37E-BDD6-439E-8689-19BA02DADA6EQ49603272-83F294F8-E309-4249-809A-A48A9051B40BQ52659368-E9B54C6A-466E-45A9-A221-81C31541CC79Q53245450-CA49B4EB-E6A0-4862-8F92-F1EDABC2218EQ54956715-6BC87605-3954-40FA-BEEA-F5412840AD97Q57904702-E07FC99F-05A6-4D08-9A09-7A880AB57E95
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Myeloma bone disease.
@ast
Myeloma bone disease.
@en
Myeloma bone disease.
@nl
type
label
Myeloma bone disease.
@ast
Myeloma bone disease.
@en
Myeloma bone disease.
@nl
prefLabel
Myeloma bone disease.
@ast
Myeloma bone disease.
@en
Myeloma bone disease.
@nl
P1476
Myeloma bone disease.
@en
P2093
Callander NS
Roodman GD
P304
P356
10.1016/S0037-1963(01)90020-4
P577
2001-07-01T00:00:00Z